Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid Tumors.
Austin RJ, Lemon BD, Aaron WH, Barath M, Culp PA, DuBridge RB, Evnin LB, Jones A, Panchal A, Patnaik P, Ramakrishnan V, Rocha SS, Seto P, Sexton K, Strobel KL, Wall R, Yu S, Yu TZ, Law CL, Baeuerle PA, Wesche H. Austin RJ, et al. Among authors: culp pa. Mol Cancer Ther. 2021 Jan;20(1):109-120. doi: 10.1158/1535-7163.MCT-20-0061. Epub 2020 Nov 17. Mol Cancer Ther. 2021. PMID: 33203731
Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms.
Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, Su M, Sho M, Steinle R, Wong MH, Evangelista F, Grove J, Cardenas M, James M, Hsi ED, Chao DT, Powers DB, Ramakrishnan V, Dubridge R. Culp PA, et al. Clin Cancer Res. 2010 Jan 15;16(2):497-508. doi: 10.1158/1078-0432.CCR-09-1929. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068083
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.
Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D. Lam ET, et al. Among authors: culp pa. Mol Cancer Ther. 2018 Jan;17(1):215-221. doi: 10.1158/1535-7163.MCT-17-0330. Epub 2017 Oct 20. Mol Cancer Ther. 2018. PMID: 29054986 Free PMC article. Clinical Trial.
Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts.
de Plater L, Vincent-Salomon A, Berger F, Nicolas A, Vacher S, Gravier E, Thuleau A, Karboul N, Richardson M, Elbaz C, Marangoni E, Bièche I, Paoletti X, Roman-Roman S, Culp PA, Asselain B, Diéras V, Decaudin D. de Plater L, et al. Among authors: culp pa. PLoS One. 2014 Nov 6;9(11):e104227. doi: 10.1371/journal.pone.0104227. eCollection 2014. PLoS One. 2014. PMID: 25375638 Free PMC article.
18 results